Hoth Therapeutics Dirección
Dirección controles de criterios 2/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Robb Knie
Chief Executive Officer (CEO)
US$1.9m
Compensación total
| Porcentaje del salario del CEO | 25.17% |
| Permanencia del CEO | 9yrs |
| Participación del CEO | 2.9% |
| Permanencia media de la dirección | 7.2yrs |
| Promedio de permanencia en la Junta Directiva | 6.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Hoth Therapeutics (NASDAQ: HOTH): Small-Cap Biotech Pairing Clinical Breakthroughs with AI Innovation
Hoth Therapeutics (NASDAQ: HOTH) is emerging as one of the most intriguing small-cap biotech stories on the market. With a market capitalization of just ~$16 million, the company is combining tangible clinical success with cutting-edge AI tools, creating a potentially asymmetric investment opportunity.Weekly Picks: 💸 A fintech heavyweight with even more upside potential and 2 more picks
This week’s picks cover: Why Venmo and merchant solutions are driving PayPal’s upside potential, how IREN’s pivot from Bitcoin mining to AI infrastructure is adding value, and how Cadeler’s fleet expansion rides offshore wind growth.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Strengthening Pipeline with Breakthrough AI Hoth Therapeutics (NASDAQ: HOTH) is layering cutting-edge technology on top of its strong clinical momentum. Already known for its standout Phase 2 trial results (100% patient improvement with HT-001 cancer rash trial), Hoth is now integrating Lantern Pharma’s PredictBBB.ai platform , an AI tool with 94% accuracy in predicting whether drugs can cross the blood–brain barrier (BBB).100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury
Hoth Therapeutics (NASDAQ:HOTH) said on Tuesday it had signed an agreement with Altasciences to develop and manufacture the HT-TBI drug product formulation for the treatment and/or prevention of secondary brain injury. HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals, and military personnel. "We are leveraging Altasciences' expertise to develop and manufacture novel parenteral formulations to achieve a formulation that requires no preparation or special storage requirements to ensure HT-TBI can be used anywhere in the field at the time a head injury or stroke occurs," the company said.Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule
Nasdaq has granted Hoth Therapeutics (NASDAQ:HOTH) an additional 180-days or until December 26, 2022 to regain compliance with minimum $1.00 closing bid price per share requirement. In a letter dated December 30, 2021, the company was notified that the minimum bid price per share for its common shares has been below $1.00 for a period of 30 consecutive business days and it no longer meets the minimum bid price requirements. The company having provided written notice of its intention to cure the deficiency during the Additional Compliance Period, including by effecting a reverse stock split, if necessary. If the company does not comply with the minimum bid price requirement during the 180-day grace period than its shares are subject to delisting. Shares plunged around 72% over a period of one year.Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$12m |
| Dec 31 2025 | US$2m | US$486k | -US$12m |
| Sep 30 2025 | n/a | n/a | -US$12m |
| Jun 30 2025 | n/a | n/a | -US$10m |
| Mar 31 2025 | n/a | n/a | -US$10m |
| Dec 31 2024 | US$1m | US$450k | -US$8m |
| Sep 30 2024 | n/a | n/a | -US$8m |
| Jun 30 2024 | n/a | n/a | -US$8m |
| Mar 31 2024 | n/a | n/a | -US$8m |
| Dec 31 2023 | US$846k | US$450k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | n/a | n/a | -US$11m |
| Dec 31 2022 | US$1m | US$450k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$11m |
| Jun 30 2022 | n/a | n/a | -US$12m |
| Mar 31 2022 | n/a | n/a | -US$13m |
| Dec 31 2021 | US$1m | US$400k | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$10m |
| Mar 31 2021 | n/a | n/a | -US$10m |
| Dec 31 2020 | US$781k | US$350k | -US$7m |
| Sep 30 2020 | n/a | n/a | -US$10m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$9m |
| Dec 31 2019 | US$2m | US$350k | -US$8m |
Compensación vs. Mercado: La compensación total de Robb($USD1.93M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD649.34K).
Compensación vs. Ingresos: La compensación de Robb ha aumentado mientras la empresa no es rentable.
CEO
Robb Knie (56 yo)
Mr. Robb Knie is Founder of Hoth Therapeutics, Inc. Mr. Knie served as the Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors of FoxWayne Enterprises Acquisition Corp....
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 9yrs | US$1.93m | 2.86% $ 328.4k | |
| Chief Financial Officer | 7.2yrs | sin datos | sin datos | |
| Executive Vice President of Operations | 4yrs | sin datos | sin datos |
Equipo directivo experimentado: El equipo directivo de HOTH es experimentado (7.2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 9yrs | US$1.93m | 2.86% $ 328.4k | |
| Member of Scientific Advisory Board | 8.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 4.3yrs | sin datos | sin datos | |
| Independent Director | 7.8yrs | US$50.00k | 0.0052% $ 600.2 | |
| Member of Scientific Advisory Board | 6.4yrs | sin datos | sin datos | |
| Independent Director | 6.1yrs | US$56.00k | 0.00070% $ 80.3 | |
| Member of Scientific Advisory Board | 6.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 3.4yrs | US$50.00k | 0.027% $ 3.0k | |
| Member of Scientific Advisory Board | 4.3yrs | sin datos | sin datos | |
| Independent Director | 1yr | US$32.36k | sin datos |
Junta con experiencia: La junta directiva de HOTH se considera experimentada (6.1 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 20:28 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Hoth Therapeutics, Inc. está cubierta por 1 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |